The Life Sciences team advised Dragonfly Therapeutics, Inc. in its strategic collaboration with Merck, through a subsidiary, to discover, develop and commercialize innovative immunotherapies for patients with solid tumor cancers. The collaboration grants Merck the option to license exclusive worldwide intellectual property rights to products developed using Dragonfly's TriNKET™ technology platform for a number of solid-tumor programs, with the potential to earn Dragonfly up to $695 million in upfront and milestone payments per program as well as royalties on sales of approved products.
Dragonfly Therapeutics is committed to discovering, developing and commercializing therapies that use its novel TriNKET™ technology to harness the body's innate immune system to bring breakthrough cancer treatments to patients.
The Goodwin team was led by partner Lawrence Wittenberg.
For additional details on the deal, please read the press release.